Septerna president Bhatt sells $115,860 in shares
Septerna, Inc. President and COO Elizabeth Bhatt sold 4,000 shares of common stock for a total of $115,860 on February 18, 2026, following a 370% stock surge over the past year. Concurrently, Bhatt exercised options to acquire an equal number of shares. The transactions were initiated under a Rule 10b5-1 sales plan and leave Bhatt with 174,209 directly owned shares in the biotech company.
Insider Selling: Septerna (NASDAQ:SEPN) COO Sells 4,000 Shares of Stock
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of company stock on February 18th for a total of $115,880, reducing her direct ownership by 2.24%. Following the sale, she still holds 174,209 shares valued at over $5 million. The stock traded up 0.7% to $27.28, and the company has mixed analyst ratings with an average price target of $33.83.
Septerna (NASDAQ:SEPN) Trading Down 5.9% - Here's What Happened
Septerna (NASDAQ:SEPN) experienced a 5.9% drop in its stock price during mid-day trading, with significantly lower trading volume compared to its average. While Wall Street analysts have a "Moderate Buy" consensus rating with an average target price of $33.83, recent analyst actions have been mixed, with some upgrades and some downgrades. The company, a clinical-stage biotechnology firm focused on GPCR oral small molecule drug discovery, has also seen institutional investors increasing or initiating positions.
Septerna Inc stock hits all-time high at 30.51 USD
Septerna Inc.'s stock reached an all-time high of $30.54, reflecting a significant 112.19% increase over the past year and a 134.64% return in the last six months. This surge is attributed to strong investor confidence, a solid financial position, and positive developments including upcoming clinical trial data presentations and strategic leadership appointments. Analysts maintain a "Strong Buy" consensus with price targets up to $43, despite expectations of no profitability this year.
Septerna (NASDAQ:SEPN) Shares Up 9.4% - Here's What Happened
Septerna (NASDAQ:SEPN) shares rose 9.4% on Tuesday, trading at approximately $30.09 on unusually light volume. The clinical-stage biotech company, focused on GPCR oral small-molecule drug discovery, has a "Moderate Buy" consensus rating from analysts with an average price target of $33.83. Several institutional investors have recently adjusted their holdings in Septerna, which has a market cap of $1.36 billion.
Septerna Inc stock hits all-time high at 30.51 USD
Septerna Inc. stock has reached an all-time high of $30.54, reflecting a 112.19% surge over the past year and a 630% climb from its 52-week low. This growth is supported by strong investor confidence, a solid financial position, and a "Strong Buy" analyst consensus with a high price target of $43, despite anticipated unprofitability this year. The company is also advancing its drug discovery efforts and making strategic leadership appointments.
How Early SEP-631 Data at AAAAI 2026 Will Impact Septerna (SEPN) Investors
Septerna, Inc. (SEPN) is set to present its first-in-human Phase 1 clinical data for SEP-631, an oral MRGPRX2-targeting therapy for chronic spontaneous urticaria, at the 2026 AAAAI Annual Meeting. This data release is a crucial near-term catalyst for investors, especially after a previous pipeline setback, and will help determine the potential of their GPCR platform. The company's investment narrative depends on its ability to translate early science into successful, partnerable drugs, with the SEP-631 data being key to validating its approach in mast cell-driven diseases.
How Early SEP-631 Data at AAAAI 2026 Will Impact Septerna (SEPN) Investors
Septerna Inc. will present early Phase 1 clinical data for SEP-631, an oral therapy for mast cell-driven diseases, at the 2026 AAAAI Annual Meeting. This data release is a key near-term catalyst for investors to assess the potential of Septerna's GPCR platform and its MRGPRX2 approach. The article highlights that investor opinions on Septerna are already varied, and the upcoming data will be crucial in shaping the company's investment narrative, particularly with a stock valuation that appears to be on the expensive side.
Septerna Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
Septerna, Inc. announced an inducement grant to Mark A. Wilson, its Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock. The grant, made on February 6, 2026, has an exercise price of $25.41 per share and vests over four years, aligning with Nasdaq Listing Rule 5635(4) as an inducement for his employment. Septerna is a clinical-stage biotechnology company focused on GPCR drug discovery.
Septerna to present phase 1 data for SEP-631 at AAAAI meeting
Septerna, Inc. is set to present Phase 1 clinical trial data for its drug candidate SEP-631 at the American Academy of Allergy Asthma & Immunology Annual Meeting. The presentation will detail the first-in-human study of SEP-631, an oral small molecule targeting the MRGPRX2 receptor for chronic spontaneous urticaria and other mast cell-driven diseases. Analysts have issued "strong buy" ratings for Septerna with price targets indicating significant upside, reflecting optimism about the company's clinical advancements and proprietary drug discovery platform.
Septerna to present phase 1 data for SEP-631 at AAAAI meeting
Septerna, Inc. will present Phase 1 clinical trial data for SEP-631, an oral small molecule targeting chronic spontaneous urticaria, at the American Academy of Allergy Asthma & Immunology Annual Meeting. The presentation will detail a first-in-human study of SEP-631's mechanism of action as a negative allosteric modulator of MRGPRX2. Analysts have a strong buy consensus with price targets suggesting significant upside as the company advances its clinical programs.
Viatris Septerna BIO Takeda name new legal chiefs
Viatris, Septerna Inc., the Biotechnology Innovation Organization (BIO), and Takeda have announced new legal leadership appointments. Matthew J. Maletta will become CLO at Viatris, Mark A. Wilson will join Septerna as CLO, Joe Franklin, JD, PhD, is the new chief legal and policy officer for BIO, and Natalie Furney will join Takeda's executive team for its Global Legal, Ethics & Compliance unit. These appointments reflect a reshuffling of legal leadership across the pharmaceutical and biotechnology sectors.
Early trial tests oral therapy for mast cell diseases at 2026 allergy meeting
Septerna will present Phase 1 data for SEP-631, an oral MRGPRX2 negative allosteric modulator designed for mast cell-driven diseases, at the 2026 AAAAI Annual Meeting. The presentation will detail a first-in-human, proof-of-mechanism study using short wave infrared imaging to assess the response to an icatibant skin challenge in conditions like chronic spontaneous urticaria. This announcement follows earlier milestones for SEP-631 and Septerna's strategic shift in its pipeline.
Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Septerna, Inc. (NASDAQ:SEPN) has received a "Moderate Buy" consensus rating from eight analysts, with an average one-year price target of $33.83. Despite this, the company reported weak recent financial results, missing EPS and revenue estimates, and shows negative return on equity and net margin. Insider selling and institutional buying activity are also noted, with the stock currently trading near $25.
Short Interest in Septerna, Inc. (NASDAQ:SEPN) Increases By 36.0%
Septerna, Inc. (NASDAQ:SEPN) saw a significant increase in short interest by 36.0% in January, reaching 1,941,013 shares, which represents about 4.5% of the company's stock. This comes as the company recently reported an earnings and revenue miss. Mixed signals from analysts and insiders include an average "Moderate Buy" rating with a target price of $33.83, while an SVP recently sold shares.
HC Wainwright Issues Negative Forecast for Septerna Earnings
HC Wainwright has lowered its FY2025 EPS estimate for Septerna (NASDAQ: SEPN) to ($1.53) from ($1.45) but maintained a "Buy" rating and a $35 price target. This revision follows Septerna's recent quarterly earnings miss, where it reported ($0.09) EPS against a $0.19 consensus and $21.5M revenue versus $24.5M. Despite the negative forecast, the overall analyst sentiment remains a "Moderate Buy" with an average price target of $33.83.
Is Septerna (SEPN) Quietly Building an IP Moat with Its New Chief Legal Officer Hire?
Septerna, Inc. has appointed Mark A. Wilson as Chief Legal Officer, a move that strengthens the company's patent and collaboration strategies due to his extensive experience in pharmaceutical intellectual property. While this hire is seen as additive to Septerna's long-term investment narrative by potentially building an "IP moat," it is not expected to immediately impact short-term clinical or commercial milestones. The article suggests that despite this strategic legal enhancement, Septerna is projected to remain unprofitable for several years, and its stock is currently trading beyond its estimated value according to some analyses.
Septerna stock price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $35.00 from $30.00, maintaining a Buy rating. This adjustment reflects an updated valuation model, a lower discount rate, and revised forecasts for EBIT margin and sales. Septerna is also anticipating initial Phase 1 trial data for its oral treatment SEP-631 in the first half of 2026, with details to be presented at an upcoming American Academy of Allergy, Asthma and Immunology meeting.
Septerna: Advancing GPCR Pipeline and De-Risked Valuation Support Upgraded Buy Rating and $35 Target
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Septerna, Inc. with a $35 price target, citing the company's advancing clinical pipeline. Key catalysts include upcoming Phase 1 data for SEP-631 in chronic spontaneous urticaria and the progression of SEP-479 for hypoparathyroidism, expected to enter human testing in 1H26. The upgraded valuation reflects pipeline developments and a revised discounted cash flow model.
Septerna stock price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $35 from $30, maintaining a Buy rating. This adjustment is based on a roll-forward of their discounted cash flow valuation and changes in discount rate and financial forecasts. The biopharmaceutical company is expected to release initial Phase 1 trial data for SEP-631 in the first half of 2026.
SEPN: HC Wainwright & Co. Updates Price Target to $35 | SEPN Sto
HC Wainwright & Co. has reaffirmed its "Buy" rating for Septerna (SEPN) and increased its price target from $30 to $35, representing a 16.67% increase. This update follows a series of positive analyst ratings for Septerna from other financial institutions, with an average target price of $33.14 from 7 analysts, implying an upside of 27.13%. Septerna, a clinical-stage biotechnology company, is focused on G protein-coupled receptor (GPCR) oral small molecule drug discovery.
Septerna Appoints Mark Wilson as Chief Legal Officer
Septerna, Inc. has appointed Mark A. Wilson as Chief Legal Officer, bringing over 25 years of experience in intellectual property and corporate legal affairs to the biotechnology company. Wilson's role will involve strengthening governance, shaping IP strategy, and scaling operations as Septerna advances its GPCR-focused drug portfolio. An analyst rating on Septerna (SEPN) stock is a Buy with a $43.00 price target, though TipRanks' AI Analyst, Spark, rates it Neutral due to operational inefficiencies and negative cash flow despite strong technical momentum.
Septerna to Present GPCR Pipeline Updates at JPM Conference
Septerna, Inc. will present updates on its GPCR-focused pipeline and Native Complex Platform at the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. Key milestones for 2026 include initiating a Phase 1 trial for SEP-479, presenting Phase 1 data for SEP-631, and advancing its TSHR program, alongside its alliance with Novo Nordisk. Currently, analysts rate SEPN stock as a Hold with a price target of $27.00.
Septerna, Inc. Announces Key Developments at J.P. Morgan Healthcare Conference
Septerna, Inc. announced significant progress in GPCR drug discovery at the J.P. Morgan Healthcare Conference on January 12, 2026. Key updates include the initiation of a Phase 1 trial for SEP-479 in hypoparathyroidism in early 2026, anticipated Phase 1 results for SEP-631 in mast cell diseases by March 2026, and a collaboration with Novo Nordisk for metabolic diseases. The company also projects its cash runway to extend into 2029, supported by its Native Complex Platform aimed at expanding druggable GPCR targets.
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Rating of "Moderate Buy" by Brokerages
Septerna, Inc. (NASDAQ:SEPN) has received a "Moderate Buy" consensus rating from seven brokerages, with an average one-year price target of $33.00. Despite missing recent quarterly earnings and revenue estimates, major funds have increased their positions in the company, though insiders have sold shares. Analysts project a FY EPS of -7.11, and the stock currently has a market capitalization of $1.15 billion.
Septerna Appoints Mark Wilson as Chief Legal Officer
Septerna, Inc. has appointed Mark A. Wilson as Chief Legal Officer, bringing over 25 years of experience in intellectual property, corporate legal affairs, and corporate governance to the company. Wilson's role will involve strengthening governance, shaping global IP strategy, and scaling operations as Septerna advances its GPCR-focused drug portfolio. The company, a clinical-stage biotechnology firm, specializes in developing novel oral small-molecule drug candidates.
Septerna appoints Mark Wilson as chief legal officer By Investing.com
Septerna, Inc., a clinical-stage biotechnology company, has appointed Mark A. Wilson as its Chief Legal Officer. Wilson brings over 25 years of experience in the pharmaceutical and biotech industries, previously serving at Nektar Therapeutics. The company, valued at $1.15 billion, maintains a strong financial position and analysts anticipate significant sales growth.
Septerna appoints Mark Wilson as chief legal officer By Investing.com
Septerna, Inc. has announced the appointment of Mark A. Wilson as Chief Legal Officer. Wilson brings over 25 years of experience in the pharmaceutical and biotech industries, having previously served at Nektar Therapeutics. The clinical-stage biotechnology company, valued at approximately $1.15 billion, focuses on G protein-coupled receptor (GPCR) drug discovery and has received optimistic analyst ratings and price targets for its pipeline.
Septerna Appoints Mark Wilson as Chief Legal Officer
Septerna, Inc. has announced the appointment of Mark A. Wilson as Chief Legal Officer, bringing over 25 years of experience in intellectual property, corporate legal affairs, strategic collaborations, and corporate governance. Wilson will be instrumental in enhancing Septerna's governance framework, developing its global IP strategy, and supporting the scaling of its operations. The company also faces challenges with operational inefficiencies and negative cash flow, despite having strong technical momentum and strategic board expansion.
Septerna, Inc. Expands Leadership with New Chief Legal Officer
Septerna, Inc. announced the appointment of Mark A. Wilson as its new Chief Legal Officer on January 8, 2026. Wilson brings over 25 years of legal and biotech experience to the role, which will be crucial for enhancing Septerna's governance and intellectual property strategy and scaling its long-term objectives. He previously served as Chief Legal Officer at Nektar Therapeutics.
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna, Inc. (Nasdaq: SEPN) announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson brings over 25 years of experience in intellectual property, corporate legal matters, strategic collaborations, and corporate governance in the pharmaceutical and biotech sectors. This appointment is expected to strengthen Septerna's governance framework and intellectual property strategy as the company advances its GPCR drug discovery platform and pipeline.
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline
Jones Trading initiated coverage on Septerna Inc (NASDAQ:SEPN) with a Buy rating and a price target of $43.00, citing the company's strong GPCR pipeline and potential for significant market share in hypoparathyroidism and chronic spontaneous urticaria treatments. Septerna's lead programs, SEP-479 and SEP-631, are expected to enter clinical trials in 2026, with revenue projections of $2.5 billion and $3.2 billion respectively by 2035. The company also benefits from a collaboration with Novo Nordisk, ensuring financial stability into 2029.
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline
Jones Trading initiated coverage on Septerna Inc (NASDAQ:SEPN) with a Buy rating and a $43.00 price target, citing the company's robust pipeline of small molecule therapies targeting G protein-coupled receptors (GPCRs). Septerna, a clinical-stage biotech focusing on two lead programs, SEP-479 for hypoparathyroidism and SEP-631 for chronic spontaneous urticaria, is projected to achieve significant peak U.S. sales by 2035 for both assets. The company benefits from a collaboration with Novo Nordisk, extending its cash runway into 2029, and has garnered strong support from multiple analysts.
Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading
Jones Trading initiated coverage on Septerna (NASDAQ:SEPN) with a "buy" rating and a $43.00 price target, suggesting a potential upside of 45.91%. This follows other analysts' actions, including Raymond James with a "strong-buy" and Wells Fargo upgrading to "overweight," contributing to a consensus "Moderate Buy" rating with a $33.00 price target. Despite missing recent earnings estimates and trading with negative margins, Septerna's stock is near a 1-year high, reflecting mixed analyst sentiment and market performance.
Jones Trading Initiates Coverage of Septerna (SEPN) with Buy Recommendation
Jones Trading has initiated coverage on Septerna (NASDAQ:SEPN) with a Buy recommendation. Analysts project an average one-year price target of $30.80/share, representing a 4.53% upside from the current closing price. The article also details institutional ownership and fund sentiment, noting a bearish outlook based on the put/call ratio.
Septerna (SEPN): Valuation Check After Raymond James Buy Rating and S&P Pharma Index Inclusion
Septerna (SEPN) has seen a significant boost in visibility following a Raymond James Buy rating and inclusion in the S&P Pharmaceuticals Select Industry Index, leading to an 84% 90-day share price return. Despite trading at a 3.4x price-to-book ratio, which is above the broader US pharmaceuticals industry average, it appears reasonable when compared to a closer peer set. Investors must now assess if the current market price fully accounts for Septerna's future growth, especially given it is not yet profitable.
Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile?
Septerna, Inc. is gaining investor attention following new coverage from Raymond James and upcoming presentation at the J.P. Morgan Healthcare Conference. This increased interest highlights the company's clinical-stage pipeline and G protein-coupled receptor (GPCR) drug discovery platform. Investors need to evaluate if the GPCR platform can translate early momentum into long-term value, considering the expected losses and moderate revenue growth.
Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile?
Septerna, Inc. (SEPN) is gaining investor attention following Raymond James' positive coverage and CEO Jeffrey Finer's upcoming presentation at the J.P. Morgan Healthcare Conference. This increased interest highlights the company's G protein-coupled receptor (GPCR) drug discovery platform and clinical-stage pipeline. The new analyst coverage and recent market re-rating are shaping Septerna's investment narrative, shifting the risk profile more towards clinical execution rather than just funding.
Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile?
Septerna, Inc. is gaining investor attention with new coverage from Raymond James and an upcoming presentation at the J.P. Morgan Healthcare Conference, focusing on its G protein-coupled receptor drug discovery platform. While the new coverage and potential for revenue from a Novo Nordisk collaboration rebalance risk towards execution rather than funding, investors should be aware of a potentially high valuation and an emphasis on successful clinical trial outcomes. The article highlights both the optimism and downside, with varying fair value estimates from the investment community.
Septerna Inc stock hits all-time high at 29.79 USD By Investing.com
Septerna Inc. (SEPN) stock reached a new all-time high of $29.98, surpassing its previous 52-week high, following an impressive 162.54% price return over the last six months. The biotech firm, with a market capitalization of $1.33 billion, has also seen its stock price increase by 17.69% over the past year. Several analysts, including Cantor Fitzgerald, Wells Fargo, Raymond James, and Truist Securities, have maintained or upgraded their ratings on Septerna, citing confidence in its drug discovery platform and lead programs.
Septerna Inc stock hits all-time high at 29.79 USD
Septerna Inc (SEPN) stock has reached an all-time high of $29.98, surpassing its previous 52-week high, reflecting a 162.54% price return over the past six months and a 17.69% increase over the past year. Despite a strong analyst consensus, InvestingPro Fair Value metrics suggest the stock is slightly overvalued given its $1.33 billion market capitalization. Recent developments include maintained and upgraded analyst ratings with price targets ranging from $25.00 to $38.00, and the appointment of Dr. Keith Gottesdiener to the board.
Septerna Inc stock hits all-time high at 29.79 USD By Investing.com
Septerna Inc (SEPN) stock has reached an all-time high of $29.98, surpassing its previous 52-week high, reflecting strong market performance and investor confidence. The biotech firm has seen a 162.54% price return over the past six months and a 17.69% increase over the past year. Analysts maintain positive ratings for SEPN, with recent upgrades and new coverage highlighting the potential of its GPCR drug discovery platform and lead drug candidates.
Raymond James Initiates Coverage of Septerna (SEPN) with Strong Buy Recommendation
Raymond James has initiated coverage of Septerna (SEPN) with a Strong Buy recommendation, according to a report by Fintel. The average one-year price target for SEPN is $29.84/share, suggesting an 8.33% upside from its latest closing price. Institutional ownership in Septerna decreased slightly, with top holders including Ra Capital Management and Trv Gp V.
Raymond James initiates Septerna stock with Strong Buy rating, $38 target
Raymond James initiated coverage on Septerna Inc. (NASDAQ: SEPN) with a Strong Buy rating and a $38.00 price target, signaling a potential 38% upside from its current share price. This positive outlook is driven by Septerna's proprietary GPCR drug discovery platform, which has two promising lead programs, SEP-631 and SEP-479, and is supported by a strong financial position with a cash runway extending to 2029. The firm anticipates significant catalysts in the near future, including Phase 1 data for SEP-631 and SEP-479 entering clinical trials in the first half of 2026.
Raymond James initiates Septerna stock with Strong Buy rating, $38 target
Raymond James has initiated coverage on Septerna Inc (NASDAQ:SEPN) with a Strong Buy rating and a $38.00 price target, citing the company's proprietary GPCR drug discovery platform and strong financial position. Septerna's stock has seen a significant 162.54% gain over the past six months, and the firm anticipates major catalysts in the near future with upcoming clinical trial data for SEP-631 and SEP-479.
Raymond James Initiates Coverage on Septerna With Strong Buy Rating, $38 Price Target
Raymond James has initiated coverage on Septerna Inc. (SEPN) with a Strong Buy rating and a price target of $38. This new coverage indicates a positive outlook from the firm regarding Septerna's future performance. Septerna is a clinical-stage biotechnology company focused on developing G protein-coupled receptor (GPCR) oral small-molecule drugs.
Septerna (NASDAQ:SEPN) Coverage Initiated at Truist Financial
Truist Financial has initiated coverage on Septerna (NASDAQ:SEPN) with a "buy" rating and a $34.00 price target, suggesting a significant upside. This positive outlook contrasts with the company's recent earnings miss and negative margins. Septerna currently holds a "Moderate Buy" consensus rating from analysts, with an average target price of $29.25.
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna, Inc. announced that its CEO and co-founder, Jeffrey Finer, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:45 p.m. PT. The clinical-stage biotechnology company, focused on G protein-coupled receptor (GPCR) drug discovery, will make a live webcast of the presentation available on its investor relations website. Septerna utilizes its proprietary Native Complex Platform™ to develop a pipeline of novel oral small molecule drug candidates across various therapeutic areas.
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna, Inc. announced that its CEO and co-founder, Jeffrey Finer, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The clinical-stage biotechnology company specializes in G protein-coupled receptor (GPCR) drug discovery, utilizing its proprietary Native Complex Platform™ to develop novel oral small molecule drug candidates. A live webcast of the presentation will be available on the company's website.
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna, Inc. (Nasdaq: SEPN) announced that its CEO and co-founder, Jeffrey Finer, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The clinical-stage biotechnology company will discuss its pioneering work in G protein-coupled receptor (GPCR) drug discovery and its proprietary Native Complex Platform™. A live webcast of the presentation will be available on the company's website.
